IRICoR receives 25 million dollars to support its research commercialization activities as part of the 2018 CECR competition

Montreal, July 30, 2018 — IRICoR (Institute for Research in Immunology and Cancer – Commercialization of Research), a drug discovery and commercialization cluster, is proud to announce that it has received substantial support from the federal government in the amount of 25 million dollars, as part of the 2018 edition of the Centres of Excellence for Commercialization and Research program […]

IRICoR and Université de Montréal Enter into Research Collaboration with AbbVie to Discover Tumor-Specific Neoantigens

Montreal, June 5, 2018 – The Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) and its host institution, the Université de Montréal (UdeM) today announced that they have entered into a research collaboration with AbbVie, a global research and development-driven biopharmaceutical company, in order to identify Tumor-Specific Neoantigens (TSNA) based on a novel proprietary platform developed […]

IRICoR takes part in a life sciences mission organized by the Government of Quebec in Belgium

In collaboration with the Québec Government Office in Brussels, the Minister of Economy, Science and Innovation (MESI), organizes an economic mission in research in innovation in the life sciences sector, happening from May 14th to 17th 2018. Nadine Beauger, Chief Executive Officer of IRICoR is a member of the delegation.
This mission will allow the attending Quebec organizations to take […]

CHU Ste-Justine’s Quality & Innovation Week – Nadine Beauger invited Speaker

As part of CHU Ste-Justine’s Quality & Innovation Week, Nadine Beauger, IRICoR’s Executive Director, shared her experience and her career as a woman and scientist in the business world, at the Entrepreunariat Career Evening as guest speaker.

The “Entrepreunariat” career evening was held during a journey under the theme Personalized Health and highlighted promising initiatives and new targeted health solutions.
As Université […]

IRICoR to present at next LES workshop – Paris, France

IRICoR is proud to announce the Dr. Steven Klein, Vice-President Business Development at IRICoR is invited as a speaker at the next Licensing Executives Society – France workshop to be held April 04, 2018 in Paris.
This half-day conference focus on “Agreements between Biotech and University and between Pharma and Biotech:” what to do and what not to do “”, among […]

2018-2019 Provincial Budget – IRICoR receives $12.3 M from the MESI, a clear commitment from the government to life sciences

Montreal, March 28, 2018 — IRICoR is delighted by the government’s show of support, in the amount of $12.3M, enabling it to carry out its research project maturation activities in oncology and in immunology for the purpose of establishing partnerships with industry.
“We are proud to be able to rely on this substantial assistance from the Government of Quebec, allowing us […]

The Oncopole and IRICoR are proud to announce the winners of the Scholarship Competition – Entrepreneurship in Oncology (CEO)

Montreal, March 22, 2018 – The Oncopole and IRICoR have joined forces to launch the Scholarship Competition – Entrepreneurship in Oncology (CEO), offering the next generation of scientists an opportunity to take part in the first cohort of the new Life Sciences Entrepreneurship Development Program.
This practical and immersive program was launched by Montréal InVivo, Université de Montréal’s Faculty of Pharmacy […]

Journées québécoises de valorisation des données – Nadine Beauger invited Speaker

Nadine Beauger, Chief Executive Officer of IRICoR, participates to the first edition of the “Journées québécoises de valorisation des données” organized by the Institute for Data Valorisation (IVADO) and the Big Data Research Centre (BDRC) of Université Laval to present the innovative business model of IRICoR.
As Université de Montréal’s drug discovery and […]

IRICoR is pleased to share news from our partner, Domain Therapeutics.

Domain Therapeutics grants Bristol-Myers Squibb non-exclusive license for G protein-coupled receptor bioSens-All™ technology
Technology provides access to new generation of sensitive biosensors to enhance drug discovery
Strasbourg, France, February 27, 2018 – Domain Therapeutics, a France- and Quebec-based biopharmaceutical company that specializes in the research and development of new drug candidates that target transmembrane receptors, today announces the signing of a licensing […]

In vivo science and artificial intelligence join forces to advance tools in cancer treatment and management

Montreal, February 8, 2018 — It will become easier to discover imaging biomarkers and identify digital surrogates for modern end-points in personalized therapies, thanks to a partnership between Sylvain Meloche – Principal Investigator within the signaling and cell growth research unit at the Institute for Research in Immunology and Cancer (IRIC) along with his team, and Imagia, an […]

« Previous Page | Next Page »